Cytosorbents Corporation
General ticker "CTSO" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $41.3M (TTM average)
Cytosorbents Corporation does not follow the US Stock Market performance with the rate: -36.6%.
Estimated limits based on current volatility of 11.7%: low 3.01$, high 3.81$
Factors to consider:
- Total employees count: 129 (-13.4%) as of 2025
- US accounted for 0.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Future losses, Regulatory and compliance, Market acceptance, Reimbursement changes, Capital raising
- Current price 30.3% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.90$, 16.44$]
- 2026-12-31 to 2027-12-31 estimated range: [4.17$, 12.01$]
Financial Metrics affecting the CTSO estimates:
- Positive: with PPE of -2.8 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: Industry inventory ratio change (median), % of 0.70 <= 1.15
- Positive: 12.78 < Shareholder equity ratio, % of 13.36 <= 25.20
- Positive: -51.61 < Industry operating profit margin (median), % of -29.60
- Positive: -28.70 < Return on assets ratio (scaled to [-100,100]) of -15.65
- Positive: Interest expense per share per price, % of 6.15 <= 10.35
Short-term CTSO quotes
Long-term CTSO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $31.08MM | $35.59MM | $37.06MM |
| Operating Expenses | $63.03MM | $52.38MM | $51.81MM |
| Operating Income | $-31.95MM | $-16.79MM | $-14.75MM |
| Non-Operating Income | $1.89MM | $-5.62MM | $6.15MM |
| Interest Expense | $0.16MM | $1.40MM | $2.61MM |
| Income(Loss) | $-30.06MM | $-22.41MM | $-8.60MM |
| Taxes | $-0.81MM | $-1.69MM | $-0.40MM |
| Net Income(Loss)* | $-29.25MM | $-20.72MM | $-8.20MM |
| Stockholders Equity | $23.48MM | $11.11MM | $5.90MM |
| Inventory | $3.68MM | $2.73MM | $5.28MM |
| Assets | $52.96MM | $47.37MM | $44.18MM |
| Operating Cash Flow | $-21.66MM | $-14.43MM | $-12.38MM |
| Capital expenditure | $0.94MM | $0.28MM | $0.16MM |
| Investing Cash Flow | $-0.94MM | $-0.67MM | $-0.41MM |
| Financing Cash Flow | $14.47MM | $9.33MM | $9.31MM |
| Earnings Per Share** | $-13.10 | $-7.61 | $-2.63 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.